Satsuma Pharma STSA made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per share.
Satsuma has listed its shares on the Nasdaq under the ticker symbol "STSA."
Satsuma Pharma IPO: What You Need To Know
Founded in June 2016, Satsuma is a clinical-stage biopharma company developing a novel therapeutic product for the acute treatment of migraines.
Its product candidate STS101 is a drug-device combination of a proprietary dry powder formulation of dihydroergotamine mesylate, or DHE, for quick and easy administration using a pre-filled, single-use, nasal delivery device.
Credit Suisse, SVB Leerink and Evercore are the underwriters for the offering.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
